What is Osmind, Inc.?
Founded in 2020 and headquartered in San Francisco, California, Osmind, Inc. is a forward-thinking organization dedicated to advancing mental health care. The company is at the forefront of innovative treatments, with a particular focus on legal psychedelic medicine. This includes FDA-approved therapies such as ketamine and esketamine (Spravato), as well as treatments currently in clinical trials like MDMA and psilocybin. Osmind's commitment to integrating cutting-edge therapeutic approaches positions it as a key player in the evolving landscape of mental health solutions.
How much funding has Osmind, Inc. raised?
Osmind, Inc. has raised a total of $57M across 3 funding rounds:
Angel/Seed
$2M
Series A
$15M
Series B
$40M
Angel/Seed (2020): $2M with participation from What If Ventures, General Catalyst Partners, 20|20 Fund, and Jeffrey Leiden MD
Series A (2021): $15M led by Future Ventures, Tiger Global, AME Cloud Ventures, Offline Ventures, and General Catalyst
Series B (2022): $40M supported by DFJ Growth
Key Investors in Osmind, Inc.
DFJ Growth
DFJ Growth is a late-stage global venture capital firm that provides capital to companies in seed, early, and growth-stages. DFJ Growth invests in growth stage technology companies that are scaling rapidly and poised for market leadership.
Future Ventures
Future Ventures is a venture capital firm that supports mission-driven founders who are forging the future by backing visionary entrepreneurs with unique ideas. They focus on seed and early-stage investments in purpose-driven individuals who have the potential to reinvent industries.
AME Cloud Ventures
AME Cloud Ventures is a venture fund led by Jerry Yang, co-founder of Yahoo!, focusing on seed to later stage companies that build infrastructure and value chains around data. The firm invests in technology-heavy companies that gather or create unique data across various stages of the data stack, from infrastructure to applications.
What's next for Osmind, Inc.?
The recent major strategic investment into Osmind, Inc. signals a critical growth phase for the company. This influx of capital is expected to fuel further development of its innovative mental health treatments, particularly in the burgeoning field of psychedelic medicine. With a clear trajectory from its initial seed funding through Series A and into Series B, Osmind is well-positioned to scale its operations, expand its research initiatives, and potentially broaden access to its novel therapeutic modalities. The company's strategic focus on evidence-based, advanced treatments suggests a future aimed at transforming patient care and outcomes in mental health.
See full Osmind, Inc. company page
